Thermalsole und Schwefelbad Bentheim GmbH — Clinical Trial Site

101 Registered trials

41 Currently recruiting

Organisation

Thermalsole und Schwefelbad Bentheim GmbH

Location

Bad Bentheim, Germany

Identifier

ORG-100041599

Address

Am Bade 1, 48455, Germany

Departments

#40740: Dermatology
#7214;Dermatologie
2151: Klinisches Studienzentrum
2201:Dermatologie
40740:Dermatology
43001: Fachklinik Bad Bentheim Klinisches Studienzentrum
5252: Fachklinik Bad Bentheim Klinisches Studienzentrum
9195: Dermatologie
Abteilung für Dermatologie
Clinical Study Center
Clinical Trial Center
Department Dermatologie
Department of Dermatology
Dept. of Dermatology
Dept. of. Dermatology
Dermatologie
Dermatologie – Fachklinik Bad Bentheim
Dermatologische Studienambulanz
Dermatology
Dermatology Department
DEU02816: Klinisches Studienzentrum
Fachabteilung Dermatologie
Fachbereich Dermatologie und Allergologie
Fachklinik Bad Bentheim
Fachklinik Bad Bentheim – Dermatologie
Fachklinik Bad Bentheim , Klinisches Studienzentrum
Fachklinik Bad Bentheim Abteilung für Dermatologie
Fachklinik Bad Bentheim Abteilung für Rheumatologie
Fachklinik Bad Bentheim Fachbereich Dermatologie
Fachklinik Bad Bentheim Klinisches Studienzentrum
Fachklinik Bad Bentheim, Klinisches Studienzentrum
Klinik fuer Dermatologie
Klinik fuer Dermatologie und Allergologie
Klinik fur Dermatologie
Klinisches Studienzentrum
Klinisches Studienzentrum Am Bade 1
N/A
NA
Practice
Specialized clinic Bad Bentheim Department of Dermatology
Thermalsole- und Schwefelbad Bentheim GmbH
Tsianakas "Specialized clinic Bad Bentheim Department of Dermatology"

Clinical trials at this site (101)

Search interface

Study to Evaluate the Efficacy and Safety of ATI-045 in Atopic Dermatitis Not authorised

2024-520302-19-00 Atopic dermatitis 4
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
A Phase 2 trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis suppurativa Pending

2025-522831-33-00 Hidradenitis Suppurativa 4
A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending

2025-524078-40-00 Chronic Spontaneous Urticaria 5
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting

2025-522878-36-00 Chronic Spontaneous Urticaria 5 2026-04-20
Dose-finding study of LAD603 in adults with alopecia areata Recruiting

2025-523342-27-00 Alopecia areata 4 2026-04-10
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting

2024-520337-80-00 Palmoplantar Pustulosis 5 2026-01-07
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Recruiting

2024-519795-11-00 Atopic Dermatitis 4 2025-10-06
Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting

2024-520107-12-00 Hidradenitis Suppurativa // Prurigo Nodularis // Vitili 5 2025-09-03
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A study to investigate improvement in pruritus of Lichen Simplex Chronicus with dupilumab injections compared with placebo in male and femal… Recruiting

2024-514737-37-00 Neurodermatitis 5 2025-03-06
Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting

2024-511879-16-00 Prurigo Nodularis 5 2024-12-12
A Phase 3 Study With Randomized Withdrawal/Dose Up Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants With… Recruiting

2023-505804-42-00 NON SEGMENTAL VITILIGO 5 2024-07-10
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-507039-39-00 Moderate to Severe Plaque Psoriasis 5 2024-03-22
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Ato… Recruiting

2022-501478-21-00 Atopic Dermatitis Eczema 5 2024-03-15
Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica… Recruiting

2023-506548-18-00 Dermatitis atopic 10 2022-11-10
Dose Ranging Study of ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis (EVERLAST-B) Recruiting

2025-523797-17-00 Moderate-to-Severe Plaque Psoriasis 4 2026-05-08
A Phase 3 Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less… Recruiting

2025-522567-15-00 Plaque Psoriasis 5 2026-04-28
Phase 3 Efficacy and Safety of Lebrikizumab in Adults With Nummular Eczema (LUMINE) Recruiting

2025-522403-17-00 Nummular Dermatitis 5 2026-04-10
A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting

2025-522578-35-00 Atopic Dermatitis 4 2026-03-30